Alejandro Forner1 , 2

Hepatology · 2007–2021

A researcher in the Science corpus: 9 papers; trusts 3 researchers and is trusted by 2 researchers here, as inferred from the citation graph.

Subfields

Whom Alejandro Forner1 , 2 trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. J. Llovet
  2. Jordi Bruix1 , 2
  3. Riccardo Lencioni
  4. Yujin Hoshida
  5. P. Kamath
  6. A. Cheng
  7. M. Sherman

Who trusts Alejandro Forner1 , 2 overall

  1. Jordi Bruix1 , 2
  2. J. Llovet
  3. Peter R. Galle
  4. Amit G. Singal
  5. J. D. Yang

Papers from Alejandro Forner1 , 2's perspective

Ordered by how strongly the researchers Alejandro Forner1 , 2 trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. (Gastroenterology)
  2. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. (The Lancet Oncology)
  3. Molecular Targeted Therapies in Hepatocellular Carcinoma (Hepatology)
  4. The natural history of compensated cirrhosis due to hepatitis C virus: A 17‐year cohort study of 214 patients (Hepatology)
  5. INCIDENCE OF HEPATOCELLULAR CARCINOMA AND ASSOCIATED RISK FACTORS IN HEPATITIS C-RELATED ADVANCED LIVER DISEASE (Gastroenterology)
  6. Diagnosis and treatment of hepatocellular carcinoma. (Gastroenterology)
  7. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. (The Lancet)
  8. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival (Hepatology)
  9. A System of Classifying Microvascular Invasion to Predict Outcome after Resection in Patients with Hepatocellular Carcinoma (Gastroenterology)
  10. Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity (International Journal of Cancer)

Their papers